(Q44512144)

3 December 2017

Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial (English)

1 reference

seasonal allergic rhinitis

3 December 2017

1 reference

1 reference

Bousquet J

1

1 reference

3 December 2017

Lund VJ

2

1 reference

3 December 2017

van Cauwenberge P

3

1 reference

3 December 2017

Bremard-Oury C

4

1 reference

3 December 2017

Mounedji N

5

1 reference

3 December 2017

Stevens MT

6

1 reference

3 December 2017

El-Akkad T

7

1 reference

3 December 2017

1 August 2003

1 reference

3 December 2017

1 reference

3 December 2017

58

1 reference

3 December 2017

733-741

1 reference

3 December 2017

8

1 reference

A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force

3 December 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

The pharmacology and use of H1-receptor-antagonist drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

A double-blind placebo-controlled study of the efficacy and tolerability of ebastine against hayfever in general practice patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

Guidelines for clinical guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

Learning impairment and allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Soluble markers of allergic inflammation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Allergic rhinobronchitis: the asthma-allergic rhinitis link

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

The visual analogue scale: its use in pain measurement.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Acoustic evaluation of the efficacy of medical therapy for allergic nasal obstruction

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Comparative therapeutic studies with Tilavist

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Measuring health-related quality of life in rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Interpretation of rhinoconjunctivitis quality of life questionnaire data

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

The MOS short-form general health survey. Reliability and validity in a patient population

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Asthma: an inflammatory mediator soup

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Tri-Nasal triamcinolone acetonide nasal spray 200 and 400 micrograms qd versus placebo and Nasacort triamcinolone acetonide nasal aerosol 440 micrograms qd in patients suffering from seasonal allergic rhinitis during the grass season.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Therapeutic options in ocular allergic disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

Joint Task Force Algorithm and Annotations for Diagnosis and Management of Rhinitis.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2003.00076.X

7 January 2021

10.1034/J.1398-9995.2003.00076.X

Identifiers

DOI

1 reference

3 December 2017

1 reference